A Phase Ib Study of NVX-508 in Sickle Cell Disease
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This Phase 1b study in adults with sickle cell disease (SCD) in steady-state (non-acutely
ill) aims to evaluate safety and toxicity of NVX-508 in a multi-dosing paradigm as well as to
determine the maximum tolerated dose (MTD) in this population. The information gained from
this study will be used in making decisions about the appropriate dose(s) and dosing schedule
in future multicenter studies of the efficacy of NVX-508 in the treatment of vaso-occlusive
episodes (VOE).
Phase:
Phase 1
Details
Lead Sponsor:
Amma Owusu-Ansah, MD
Collaborators:
Noguchi Memorial Institute for Medical Research NuvOx LLC NuvOx Pharma Pty Ltd